I nflammation, whether sterile or in response to pathogenic infection, is an underlying component of diverse human diseases, including acute illnesses such as sepsis and systemic inflammatory response syndrome, as well as complex chronic inflammatory and cardiometabolic diseases. Although some genetic determinants of the response to inflammatory stress have been identified, 1, 2 with evidence for differences in response to infection by ancestry, 3, 4 the genomics of inflammatory responses in humans remain poorly understood. Based on residual heritability despite recent genetic discoveries for immunologic disorders, 5, 6 there are likely to be many as-yet-unknown genomic components that regulate tissue-specific responses and clinical outcomes in inflammatory disorders. Understanding tissue level transcriptome responses to activation of innate immunity in humans has the potential to identify novel genes and pathways that modulate disease trajectories, which are not identifiable by studying static inflammatory biomarkers or through interrogation of nonhuman model organisms.
Multiple tissues and cell-types are involved in the response to proinflammatory stimuli and in the resolution of inflammation. In addition to key proteincoding genes, long intergenic noncoding (linc) RNAs are emerging as important inflammatory transcriptomic modulators [7] [8] [9] [10] with diverse tissue-specific functionality and low evolutionary conservation 11 relative to mRNAs. [12] [13] [14] We hypothesized that novel human, tissue-specific, inflammatory mRNA and lincRNA responses could be revealed through interrogation of evoked transcriptomes during experimentally controlled in vivo endotoxemia. 15 In the GENE Study (Genetics of Evoked Responses to Niacin and Endotoxemia) 16 of healthy volunteers, we used the low-dose experimental endotoxemia model (1 ng/kg lipopolysaccharide [LPS]), 15, 17 to study the blood and adipose transcriptomic response to inflammation. We observed considerable variability in clinical and blood biomarker responses and hypothesized that this variability might be driven by differences in genomic and transcriptomic responses in immune and metabolic tissues. In a proof of principle (n=1) pilot study, we probed potentially disease-relevant mRNAs and lincRNAs induced during experimental endotoxemia. 18 Here, we selected individuals with extremely high or low clinical inflammatory responses to the fixed-dose LPS stimulation, defined as the top fifth percentile versus bottom fifth percentile of the febrile and plasma cytokine (TNFα [tumor necrosis factor α] and IL [interleukin]-6) clinical inflammatory responses. In these individuals, we then performed RNA sequencing (RNA-Seq) of CD14 monocytes and adipose tissue collected before and after (2-hours for monocytes and 4-hours for adipose) administration of LPS. Marked differences in tissue induction of mRNAs and lincRNAs were identified in high and low responders, and we highlight a set of novel, predominantly nonconserved, tissue-specific endotoxemia-induced lincRNAs that may modulate inflammatory response and clinical diseases.
METHODS
RNA-Seq data are deposited at Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE76404 and GSE87290. The GENE study was approved by The University of Pennsylvania's Institutional Review Board, with regulatory oversight by the Food and Drug Administration (LPS: IND No. 5984) and a National Institutes of Health-appointed data-safety and monitoring board. All subjects provided written informed consent. Full methods are available in the Data Supplement.
RESULTS

Characteristics of High and Low Responders and Analysis of Baseline Gene Expression
Despite the marked differences in the evoked responses to endotoxemia, there were no differences in biomarkers of inflammation and cardiometabolic health at baseline before LPS in high and low responder GENE study subjects (Table 1) .
We found little evidence for sex or race differences (at fold change ≥2, false discovery rate [ Tables IV and V in the Data Supplement) . Interestingly, although only 65 genes differed in CD14 monocytes by race in our data, 24 of these genes were also reported to be differentially expressed between African and European ancestry in a separate study of CD14 monocytes. 4 There was limited evidence of differences in baseline pre-LPS gene expression (at fold change ≥2, FDR P<0.05) between high and low responders (CD14 monocytes: 27 differentially expressed genes [0.13%], 
The Magnitude of LPS-Induced Transcriptomic Response Is Consistent With the Degree of Clinical Inflammatory Response
CD14 Monocytes
There were striking LPS-induced inflammatory gene expression changes (fold change ≥2, FDR P<0.05), with striking differences between high and low responders, that is, before versus after LPS, 4768 (22.27%) differentially expressed genes in high versus 360 genes (1.7%) in low responders ( Figure 1A ). Of differentially expressed genes in low responders, 98% (n=354) overlapped with differentially expressed genes in high responders (Table VIII in the Data Supplement) , and the remaining 2% (n=6) genes had nonsignificant gene expression changes in the same direction. Although a far greater number of genes were differentially expressed in high responders, 97% (n=4277) of these genes had a change trend in the same direction in low responders. This suggests that the magnitude of transcriptional responses, rather than a unique set of gene responses, is the predominant driver of differences in systemic inflammatory responses between low and high responders. Yet, whether monocyte genes that exhibited opposite direction of differentially expressed in high versus low responders (n=124, Table IX in the Data Supplement) contribute to differences in clinical inflammatory responses requires further interrogation.
Adipose Tissue
Much fewer genes were differentially expressed during endotoxemia in adipose tissue compared with monocytes, consistent with a less direct adipose response compared with the immediate activation of circulating monocytes after intravenous LPS. In adipose of high responders, there were 421 differentially expressed genes (1.7%). In low responders, there were 124 differentially expressed genes ( Figure 1B) . Many differentially expressed genes in adipose overlapped between high and low responders, (n=105 genes, Table X in the Data  Supplement) , with the majority of others trending in the same direction in both groups. There were 9 discordant genes, shown in Table XI in the Data Supplement.
Convergence of Endotoxemia-Induced Differentially Expressed Genes Across Tissues
We focused tissue-specific analyses on the high responder group, given the almost complete overlap of differentially expressed genes with low responders and because of the higher degree of endotoxemia-induced response. For differentially expressed genes in CD14 monocytes and adipose tissue, there was substantial tissue overlap (eg, 185 of 421 differentially expressed genes in adipose); of 154 genes that overlapped and were modulated in the same direction, most were upregulated and included many known inflammatory genes (Table XII in the Data Supplement; Figure 1C ), suggesting inflammatory responses that were consistent across tissues.
CD14 Monocytes
Because of our interest in lincRNAs and their propensity to be tissue and species-specific, we selected for validation a set of monocyte lincRNAs that were differentially expressed (with P<0.01, fold change >2, and fragments per kilobase of transcript per million mapped reads [FPKM] >1). We prioritized lincRNAs with large fold changes and that were differentially expressed in CD14 monocytes and adipose tissue. We excluded potential candidates when effective primers could not be designed. We assessed expression of 10 lincRNAs by quantitative polymerase chain reaction (qPCR) in samples from 6 subjects that had undergone RNA-seq (technical validation) and in 6 subjects from the GENE Study who had high inflammatory responses but were not in the RNA-seq study (biological replication). Characteristics of validation and replication subjects are shown in Table XIII 
Adipose Tissue
Using the same criteria (with P<0.01, fold change >2, and FPKM >1) as in CD14 monocytes, we selected 5 adipose differentially expressed lincRNAs for validation by qPCR (in n=8 subjects for technical validation, and n=7 independent GENE Study subjects for biological replication). Of the 5 candidates, 4 were also significantly modulated in the validation (linc-CDR2L, RP11-47L3.1, linc-C2CD4B-7, RP11-248E9.6), whereas 1 (linc-S1PR1) was not confirmed as differentially expressed (Figure 3) . Two of these, RP11-47L3.1 and RP11-248E9.6, are conserved in mouse.
Divergent Tissue-Specific Expression Responses to Endotoxemia
Of differentially expressed genes that overlapped in CD14 monocytes and adipose tissue, ≈15% (n=31) were actually differentially expressed in the opposite direction; 17 were upregulated in CD14 monocytes but down in adipose, and 14 were downregulated in CD14 monocytes but up in adipose (Table 2 ). There were no clear functional categories with evidence for enrichment within these genes (data not shown). We selected a subset for experimental validation, prioritizing those with FPKM >1 and FDR-adjusted P<0.01. We selected 11 tissue-specific divergent mRNAs for experimental validation and confirmed using qPCR in both validation and replication samples as described above, the divergent trend for all of them ( Figure 4B ), reaching statistical significance in almost all cases except PDE4B in adipose and ARNTL in monocytes, which displayed nonsignificant trends (P<0.1) in the anticipated direction. Furthermore, significant downregulation in CD14 monocytes and upregulation in adipose was confirmed for lincRNA RP11-362F19.1 (Figure 4A ), a lincRNA conserved in mouse. We consider all of these tissue-divergent differentially expressed genes to be of particular interest as candidates for unique tissue-specific functional responses to inflammation.
Functional Pathway Analyses of CD14 Monocytes and Adipose Differentially Expressed Genes
We hypothesized that the LPS-modulated genes in high responders would signal within common functional pathways, with some activated in both monocytes and adipose and others being tissue-specific. As expected, we found strong enrichment of upregulated genes in known inflammatory and stress response pathways in both monocytes and adipose (eg, Gene Ontology terms: chemokine activity, chemokine receptor binding, defense response, immune response, inflammatory response, all Bonferroni-corrected P≤0.01). Apoptosis-related genes were also upregulated in both tissues (eg, Gene Ontology terms: apoptosis, negative regulation of apoptosis, programmed cell death, negative regulation of programmed cell death, P<0.005). Tissue-specificity was apparent in monocytes, but not adipose, with enrichment of monocyte upregulated genes in protein metabolism (Gene Ontology terms: protein metabolic process, protein amino acid phosphorylation, posttranslational protein modification, P<0.05) and downregulated genes for mitochondrial activity (Gene Ontology terms: mitochondrion, P=1.2×10 -9 ). Full results at Bonferroni-corrected P ≤0.01 are presented in Table XIV in the Data Supplement.
Tissue-Specific Modulation of lincRNAs by Endotoxemia
Lack of Conservation of LPS-Modulated lincRNAs
LPS-induced differentially expressed lincRNAs were no more likely to be syntenic nor to be conserved between human and mouse than lincRNAs that were not modulated by LPS (Fishers exact P>0.5 for both monocytes and adipose). This suggests that human lincRNAs associated with inflammatory pathophysiologies are not only restricted to those that are conserved but also include those that have recently evolved in primates.
Differentially Expressed lincRNAs in CD14 Monocytes and Adipose Are Located in CisRegulatory Regions of Immune and Metabolic Genes Respectively
The Genomic Regions Enrichment of Annotations Tool 19 facilitates analysis of the functional significance of Data shown for gene expression estimates from original RNA sequencing (RNA-seq; discovery, N=8) and quantitative polymerase chain reaction (qPCR; validation, N=12) 2 h after lipopolysaccharide (LPS). Validation (qPCR) of CD14 monocyte samples included 6 of the original RNA-seq high-responder subjects and 6 new GENE Study (Genetics of Evoked Response to Niacin and Endotoxemia) high responders. All 10 candidate lincRNAs were differently expressed in the same direction in validation samples, with 8 reaching statistical significance. Differentially expressed genes are defined as those with fold change ≥2 and an false discovery rateadjusted P<0.05. *P<0.05; **P<0.005; ***P<0.001. genomic regions by associating potential cis-regulatory features with nearby genes. Using the genomic coordinates of differentially expressed lincRNAs in CD14 monocytes of high responders, we detected significant enrichment of upregulated lincRNAs close to genes known to be involved in immune functions and cytokine secretion based on annotations in the Molecular Signatures Database and Mouse phenotypes ( Figure II in the Data Supplement). In contrast, for upregulated differentially expressed lincRNAs in adipose of high responders, there was proximity enrichment for genes known to be associated with metabolic disease, including diabetes mellitus, obesity, and endocrine disorders ( Figure III in the Data Supplement). Illustrative examples of differentially expressed lincRNA proximity to inflammatory and metabolic genes, respectively, are shown in Figure IVA and IVB in the Data Supplement. These findings suggest that lincRNAs, which are highly tissue-specific, may mediate tissue-specific mRNA transcriptional responses to inflammatory stress. Indeed, of the 261 LPS-induced differentially expressed lincRNAs in CD14 monocytes of high responders, 64% were enriched in pre-LPS or post-LPS when analyzed in relation to tissuespecific expression across 15 tissues from the Illumina Human BodyMap sample, whereas only 27% of the 759 nondifferentially expressed lincRNAs were enriched (Fisher exact P<2.2×10 -6 ).
Correlation Analyses Suggests Coregulation of lincRNA and mRNA Expression
Transcriptional activation or repression of some lincRNAs and mRNAs during endotoxemia may be correlated, either because of direct regulation of mRNAs by lincRNAs, physical proximity, and shared promoters or because of coregulation in common functional pathways (eg, downstream of shared master transcriptional regulators). We examined whether differentially expressed mRNAs and lincRNAs in CD14 monocytes of high responders were correlated, defined as an absolute correlation ≥0.8 between the change in gene expression of a differentially expressed mRNA and lincRNA pair. Of all possible pairs, 3.5% were correlated from pre-LPS to post-LPS (Table XV in the Data Supplement). A similar number of mRNA-lincRNA pairs were correlated at baseline (3.6%) but with only ≈10% overlap between those correlated during baseline and those correlated during LPS induction. This indicates that similar proportions of mRNAs and lincRNAs may be coregulated at rest and during physiological stress but with very distinct patterns at rest and during dynamic inflammatory stress. Of all possible colocalized (defined as within 500 kb of each other) mRNA-lincRNA pairs across the genome, 5% of LPS-induced differentially expressed mRNA-lincRNA pairs were correlated, compared with an overall correlation rate of 3.5% (P=0.018, Fisher exact test), suggesting significant enrichment of differentially expressed lincRNAs that act in cis versus in trans. Of 247 differentially expressed lincRNAs in CD14 monocytes of high responders that had correlated expression with differentially expressed mRNAs, 59.1% were marked by enhancer states and 54.2% by promoter states. 42.5% of these lincRNAs were marked by both states. No significant difference was observed between proportions of lincRNAs with enhancer or promoter function (P=0.32, 2-sample test of proportions).
Finally, using public data (GSE31621), 20 evidence for myeloid-specific regulation of LPS differentially expressed lincRNAs is suggested by enrichment in binding of CEBPα at differentially expressed lincRNAs compared with nondifferentially expressed monocyte lincRNAs in human monocytes (both within the transcription start site, 18% versus 13%, P=0.04, and the gene body, 21% versus 16%, P=0.04. 
Overlap of LPS-Modulated mRNAs and lincRNAs With GWAS Signals
Using all mRNAs and lincRNAs that were differentially expressed by endotoxemia in CD14 monocytes and adipose tissue of high responders, we identified all single-nucleotide polymorphisms (SNPs) located within the differentially expressed gene transcription start and end sites. We queried these SNPs against 104 inflammation and cardiometabolic disease-related traits from the NHGRI (National Human Genome Research Institute) GWAS (Genome-Wide Association Study) catalog (Table XVI in the Data Supplement). We found significant overrepresentation of GWAS-significant SNPs in differentially expressed genes compared with nondifferentially expressed genes in CD14 monocytes (Fisher exact P=0.015) and in adipose tissue (Fisher exact P=0.017). In CD14 monocytes, we observed particularly strong signals for body mass index and other obesity-related traits (143 genes), autoimmune diseases (135 genes) cardiovascular disease, lipids, and hypertension (65 genes), and diabetes mellitus (37 genes). In adipose tissue, we also saw signals for obesity (16 genes) and autoimmune diseases (24 genes) with more modest signals for cardiovascular disease (5 genes) and diabetes mellitus (3 genes). ]; CD14 monocyte N=12, 2 h post-LPS; adipose N=15; 4 h post-LPS) in high-responder subjects. RP11-362F19.1 was significantly downregulated in CD14 monocytes and significantly upregulated in adipose tissue (adipose) during endotoxemia, both in the RNA-seq discovery analyses (see details in Table 2 ) and in the qPCR validation. *P<0.05; ***P<0.001. B, Divergent tissue-specific inflammatory-modulated mRNAs discovered by RNA-seq and validated by qPCR in high responders. Data shown for gene expression estimates from original RNA-seq (discovery; CD14 monocyte N=8, 2 h post-LPS; adipose N=13, 4 h post-LPS) and qPCR (validation; CD14 monocyte N=12, 2 h post-LPS; adipose N=15, 4 h post-LPS). In both discovery and independent validation samples, these mRNAs were regulated in the opposite directions in CD14 monocytes compared with adipose tissue during endotoxemia. *P<0.05; **P<0.005; ***P<0.001.
MOLRIL6 is a Novel Monocyte-Specific, Nonconserved lincRNA Induced During In Vivo Endotoxemia That Enhances LPSInduction of IL6
To facilitate functional validation and translation of top endotoxemia-modulated monocyte lincRNAs, first, we determined whether LPS treatment of human THP-1 monocytes in vitro recapitulated the in vivo responses of monocytes to experimental endotoxemia. We examined the expression of 11 top monocytes differentially expressed lincRNAs (Figure 2 and Figure 4A ) in THP-1 monocytes stimulated with LPS (1 μg/mL) for different time periods (0, 1, 3, 6, and 10 hours). We hypothesize that, like protein-coding genes, lincRNAs highly responsive to LPS stimulation are likely to be involved in mediating and regulating LPS-induced responses. As a proof of principle, we prioritized CTB-41I6.2/AC002091.1, a top DE lincRNA in monocytes not modulated in adipose tissue, for functional validation. Based on our functional characterization, we now refer to this as monocyte LPS-induced lincRNA regulator of IL6 (MOLRIL6). The in vitro response of MOLRIL6 to LPS in cultured THP-1 monocytes resembled that in monocytes in vivo during endotoxemia. This human lincRNA is syntenic in mouse but is not annotated in mouse lncRNA datasets, using GENCODE M4 annotation. 21 MOLRIL6, abundantly expressed in monocytes but not in adipose or human adipose stromal cell-differentiated adipocytes ( Figure 5A ), shows enhancer-like transcript signature in CD14 + human monocytes with higher H3K4me1 (enhancer) and lower H3K4me3 (promoter) histone marks at the transcription start site 22 ( Figure 5B ). Fractionation of THP-1 monocytes suggests that MOLRIL6 is expressed in both nuclear and cytoplasmic compartments ( Figure 5C ). Knockdown of MOLRIL6 with ASO (antisense oligonucleotide) did not affect the expression of its neighboring genes PIK3R5 and NTN1 (Figure 5D ), arguing against nuclear cis-regulatory actions. To study the functional impact of MOLRIL6, we examined the expression of LPS-induced inflammatory responses in THP-1 monocytes after knockdown of MOLRIL6. Knockdown of MOLRIL6 dampened LPS-induced IL6 expression ( Figure 5 ) but had no effects on other LPS-induced inflammatory genes, including CXCL9, CCL5, CCR7, and TNF, and key downstream LPS-stimulated signaling molecules, including SOCS1 and IRF4, as well as IDO1 and KYNU ( Figure VI in the Data Supplement). In non-LPS stimulated THP-1 monocytes, knockdown of MOLRIL6 reduced mRNA levels of CD86 ( Figure 5 ), a known positive regulator of IL6 production.
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DISCUSSION
Experimental human endotoxemia provides a controlled activation of innate immunity in humans for modeling genetic, clinical, environmental, and therapeutic contributions to human inflammatory diseases, including complex cardiometabolic disorders, as well as acute critical illness. 15, 24 Here, we selected 2 groups of GENE Study participants from the tails of clinical inflammatory responses to experimental endotoxemia to interrogate the tissue-level transcriptional underpinning of the differences in group responses. Individuals with a high clinical inflammatory response to LPS had greater activation of gene expression in CD14 monocytes and adipose tissue. Individuals with a low inflammatory response showed activation of a small subset of the same genes but at lower levels, with the primary differences being in the magnitude of the transcriptional response rather than in the types of genes that were activated. Several novel mRNAs and lincRNAs, many with evidence of tissue-specificity, were modulated by endotoxemia, of which a subset was validated experimentally. Genes regulated by endotoxemia were more likely to contain SNPs that have previously been implicated in inflammation and cardiometabolic disease GWAS compared with genes not differentially expressed with endotoxemia. Multiple lincRNAs, equally distributed between those conserved and nonconserved in mice, were modulated by endotoxemia in a tissue-specific manner suggesting a novel and potentially species-unique role for specific lincRNAs in human inflammatory pathophysiologies.
High and low responders had few baseline differences in well-studied biochemical markers of inflammation. This was also broadly reflected in the transcriptomic profiles at baseline. Yet, there was evidence of higher expression of a few known inflammatory genes (eg, IL8, CXCL1, CXCL2) in low responders in both monocyte and adipose at baseline; it is possible that these subtle differences reflect in vivo preconditioning because of a higher degree of chronic inflammation at baseline in low responders that leads to immune tolerance 25, 26 and thus a lower response to endotoxemia. Overall, however, these data indicate that it is difficult to predict the degree of pathophysiological response to inflammatory stress based on resting clinical, biochemical, or even transcriptomic biomarkers, a premise of most population-based epidemiological studies of inflammatory biomarkers in humans. For these reasons, our focus on genomic differences between high and low responses to controlled evoked inflammation is uniquely positioned to provide molecular insights and translational tools for understanding risk, clinical outcomes, and therapeutic opportunities in clinical disorders of acute, subacute, and chronic inflammatory stress.
As expected by design, we observed marked differences in the evoked transcriptomic response to endo-toxemia between high and low responders. There were far greater numbers of differentially expressed genes in both CD14 monocytes and adipose tissue of high responders compared with low responders. Rather than observing distinct sets of genes modulated in high and low responders, a nested subset of genes that were differentially expressed in high responders was also modulated in low responders. This is inconsistent with a hypothesis that a distinct transcriptome response, for example, preferential activation of anti-inflammatory or inflammation resolving pathways, may mediate the markedly blunted response in low responders. Thus, in individuals with low clinical inflammatory responses to innate immune stress, the magnitude of the clinical and biochemical inflammatory response seems to be determined by a marked blunting of stress-induced gene expression rather than by a specific activation of antiinflammatory molecular pathways. Because of our modest sample size, we do not have power to investigate eQTLs (expression quantitative trait loci) for differentially expressed genes; however, with additional sample analyses, we may have some power to detect tissue-specific cis-eQTLs using allele-specific expression analyses. Further studies in larger numbers are required to determine if such blunted responses are determined at the genetic, epigenetic, transcriptome, or posttranscriptional level 27 or via integration at each of these regulatory levels.
Although gene expression changes during experimental endotoxemia have been found to correlate well with gene expression changes during trauma, 28,29 our findings require additional translational study to inform clinical understanding because the relationship between the extent of transcriptome response during experimental endotoxemia and clinical outcomes is not established. Interestingly, metabolomics analysis found that metabolite response to experimental endotoxemia correlated well with clinical sepsis but only partially with systemic inflammatory response syndrome. 30 Of particular relevance to our work, the metabolomics response to LPS aligned more closely with the response observed in sepsis survivors versus nonsurvivors. Thus, a more robust immune response in the setting of acute infection may reduce pathogen replication and protect against infection and sepsis, but sustained activation during inflammation may result in multiple organ failure and worse outcomes. 30 Similarly, sustained chronic activation of an immune response in the setting of sterile inflammation, as is seen in atherosclerosis and obesity-related metabolic diseases, may drive disease progression and clinical complications. The transcriptomic response to endotoxemia was mostly convergent in CD14 monocytes and adipose tissue. In both tissues of high responders, there was significant enrichment of differentially expressed genes in pathways known to be involved in inflammation and defense, as well as enrichment in transcription factor activity and increased expression of genes that negatively regulate apoptosis. However, there were several indicators for tissue-specificity in the inflammatory stress response to endotoxemia. First, there were >30 genes significantly modulated by LPS with opposite direction of response in monocytes compared with adipose tissue. These findings are unlikely to be because of chance given the conservative threshold we used for differential gene expression (2-fold difference and FDR P<0.05) and because we validated this pattern for a subset of these genes in the original sample and in an independent set of GENE study high responders (the divergent, tissuespecific pattern was validated for all 11 mRNAs and for 1 of 2 lincRNAs tested). A few of these genes serve known inflammatory functions, yet all require functional and translational interrogation of tissue-specific roles in inflammatory pathophysiologies in vivo. Interestingly, MERTK has been shown to promote synthesis of specialized proresolving mediators during inflammation 31 and to promote macrophage efferocytosis, 32 a key function in limiting lesion progression and complications in atherosclerosis. This hints at potential differences in inflammatory resolution pathways between adipose tissue and myeloid cells. Second, pathway analysis of LPSmodulated genes revealed that in monocytes, but not adipose, protein metabolism gene pathways were activated, whereas genes involved in mitochondrial activity were suppressed, supporting the concept that a subset of transcriptional responses to inflammatory stress are unique to the specific need and function of individual cells and tissue. Third, and intriguingly, targeted interrogation suggests a specific role for LPS-modulated lincRNAs in regulating tissue-specific transcriptional responses to inflammatory stress. In some instances, these networks of inflammatory noncoding RNA may reflect unique human physiology because many LPS differentially expressed lincRNAs lack conservation in mice.
Recent data estimate >19 000 potentially functional lncRNAs in the human genome, 33 yet their roles in human diseases remains largely unexplored. Although emerging studies have implicated a small number of human monocyte and macrophage lincRNAs in inflammatory and immune responses, including lncIL7R, 34 THRIL, 35 and RP5-833A20.1, 36 most studies have focused on lincRNAs found only in mice or on human lincRNAs that are conserved in mice-yet, the vast majority of human lincRNAs have recently evolved and do not exhibit sequence conservation beyond primates. 11, 37 We are particularly interested, therefore, in human lincRNAs that are modulated by experimental endotoxemia and whether these reveal novel genes and networks for tissue-specific regulation of human inflammatory stress. We identified 261 (179 upregulated) and 42 (22 upregulated) LPS-modulated lincRNAs in monocytes and adipose, respectively, and in monocytes a substantial subset was tissue-enriched, suggesting a role for lincRNAs in tissue-specific transcriptional responses to inflammatory stress. Of particular relevance to human pathophysiology, there was no evidence for greater conservation of LPS-modulated lincRNAs, relative to non-LPS modulated lincRNAs, in monocytes or adipose. This suggests that most human lincRNAs involved in inflammatory pathophysiologies have recently evolved in primates and cannot be discovered or easily studied in mouse models. We validated by qPCR, a subset of novel LPS-modulated lincRNAs in both the original and independent samples. Such inflammatory-modulated lincRNAs warrant further triage for functional study, for example, RP11-362F19.1, which was modulated by LPS in opposite directions in monocytes and adipose tissue, suggesting an integrative but customized tissue-specific functional role in inflammatory processes.
Some lincRNAs may function in tandem with mRNAs that are in close physical proximity. Indeed, enrichment of LPS-regulated lincRNAs close to genes known to be involved in inflammation and immune cell function in monocytes and metabolic disease in adipose tissue support cis-regulation as 1 functional model for lincRNAs modulated by endotoxemia in vivo. Furthermore, LPSinduced change in expression of lincRNAs had stronger correlation with LPS-induced change in mRNAs located on the same chromosome. Using publicly available CD14 monocyte ChIP-seq (chromatin immunoprecipitation) data, we found enrichment of CEBPα (CCAAT/ enhancer-binding protein alpha) binding at LPS-modulated lincRNAs relative to non-LPS-modulated lincRNAs, supporting a role for LPS-modulated lincRNAs in transcriptional networks already known to regulate inflammatory signaling in monocytes. Of particular relevance to human pathophysiology and consistent with rapid evolution and expansion of lincRNAs in primate species, our human data suggest that synteny or conservation of lincRNAs with mouse is unlikely to predict whether a human lincRNA is physiologically important in human inflammatory diseases.
We observed physical overlap of specific differentially expressed mRNAs and lincRNAs with SNPs previously established as genome-wide significant for complex inflammatory and cardiometabolic traits. 38 In particular, strong signals in multiple monocyte differentially expressed genes were apparent for body mass index and other obesity-related traits, as well as autoimmune and inflammatory diseases. These data underscore the specific clinical and disease insights, for mRNAs and lincRNAs, provided by studying evoked transcriptome responses to innate inflammatory stress.
Functional validation of DE lincRNAs identified in our study can provide mechanistic insights and translational value. Our preliminary proof of principle studies focused on robust monocyte-specific lincRNA responses to endotoxemia. MOLRIL6 (formerly referred to as CTB-41I6.2 or AC0020901.1), a nonconserved lincRNA, is one of the top DE lincRNAs modulated by endotoxemia specifically in monocytes, but not in adipose tissue. Knockdown of MOLRIL6 selectively suppressed LPS-induced IL6 expression in THP-1 monocytes but had no effects on the expression of other LPS-induced inflammatory genes. Its knockdown also decreased the baseline expression of CD86, a known positive regulator of IL6 production, 23 suggesting that MOLRIL6 may selectively suppress LPS-induced IL6 expression through a CD86-dependent manner. IL6 plays an important role in both innate and adaptive immunity 39 and monoclonal antibodies to the IL6 receptor have proven clinical efficacy in inflammatory arthritis. 39 Although the binding partners of MOLRIL6 and the precise molecular mechanisms by which MOLRIL6 reduces IL6 and CD86 expression remain to be elucidated, the highly specific suppression of IL6 by MOLRIL6 raises the possibility that inhibition of MOLRIL6 could have therapeutic potential in IL6-driven inflammatory disorders. More broadly, this preliminary functional validation provides evidence that our tissue-level transcriptome profiling during human endotoxemia in vivo can reveal novel lincRNAs and mRNAs with functional significance and translational potential. A large number of prioritized LPS-regulated lincRNAs remains to be functionally validated. Such studies will provide deeper mechanistic insights into the tissue-specific transcriptome modulation of human innate immunity and their roles in human diseases.
Our study has unique strengths, including the use of human experimental endotoxemia as a controlled model of inflammation, the application of deep RNAseq during in vivo endotoxemia, our design and sample size for discovery in sampling from the extreme tails of the clinical response to endotoxemia, and our subfocus on inflammatory lincRNAs in 2 different tissues. Selection of CD14 monocytes allowed focused interrogation of responses in classical monocytes, the specific subset implicated in inflammatory disorders and atherosclerosis yet prevents inference regarding transcriptome modulation of patrolling monocytes 40, 41 and other emerging functional subsets 42 that may have distinct subpopulation-specific responses and physiological actions during endotoxemia and inflammatory stress. Substantial translational and functional follow up is required. In particular, our experimental model, conducted in young healthy volunteers, does not recapitulate the complex nature of clinical sepsis in terms of age of patients and severity of pathophysiological response, for example, degree of fever and hemodynamic perturbations, or the low-grade chronic inflammation present in cardiometabolic disease; the clinical relevance of specific findings in the endotoxemia model requires direct testing in clinical disease settings. Furthermore, the role of lincRNAs in orchestrating tissue-and leukocyte subpopulationspecific responses to inflammatory stress deserves further mechanistic interrogation.
In summary, our studies highlight novel findings including (1) specific differences in the degree of transcriptional activation, particularly in monocytes, between high and low clinical responders to experimental endotoxemia; (2) tissue-specific and nonspecific features of the transcriptome response to inflammatory stress; (3) novel lincRNAs that are activated during acute inflammation; and (4) evidence for enrichment of LPS-modulated transcripts at GWAS loci for complex traits, including obesity and autoimmune diseases. In particular, LPS-modulated lincRNAs, most of which are not conserved in mouse, may play key roles in regulating the degree and tissue-specificity of responses in human inflammatory pathophysiologies.
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